$12.52
Insights on Agenus Inc
Revenue is up for the last 2 quarters, 24.31M → 83.80M (in $), with an average increase of 71.0% per quarter
Netprofit is up for the last 3 quarters, -73.43M → -46.29M (in $), with an average increase of 26.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 47.8% return, outperforming this stock by 105.8%
In the last 3 years, Novo Nordisk A/s has given 229.2% return, outperforming this stock by 308.7%
0.56%
Downside
Day's Volatility :11.14%
Upside
10.64%
61.82%
Downside
52 Weeks Volatility :88.78%
Upside
70.61%
Period | Agenus Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.0% | -1.1% | 0.0% |
6 Months | -25.91% | 10.3% | 0.0% |
1 Year | -57.99% | 5.3% | 1.7% |
3 Years | -79.48% | 14.5% | -22.3% |
Market Capitalization | 155.4M |
Book Value | - $8.13 |
Earnings Per Share (EPS) | -13.8 |
PEG Ratio | 0.0 |
Wall Street Target Price | 88.75 |
Profit Margin | -157.22% |
Operating Margin TTM | -5.2% |
Return On Assets TTM | -27.51% |
Return On Equity TTM | -1278.83% |
Revenue TTM | 156.3M |
Revenue Per Share TTM | 8.74 |
Quarterly Revenue Growth YOY | 195.2% |
Gross Profit TTM | 82.6M |
EBITDA | -146.5M |
Diluted Eps TTM | -13.8 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.1 |
EPS Estimate Next Year | -12.91 |
EPS Estimate Current Quarter | -0.05 |
EPS Estimate Next Quarter | -0.15 |
What analysts predicted
Upside of 608.87%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 36.8M | ↓ 14.21% |
Net Income | -159.7M | ↑ 32.31% |
Net Profit Margin | -434.14% | ↓ 152.66% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 150.0M | ↑ 307.92% |
Net Income | -149.1M | ↓ 6.61% |
Net Profit Margin | -99.39% | ↑ 334.75% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 88.2M | ↓ 41.24% |
Net Income | -240.1M | ↑ 61.02% |
Net Profit Margin | -272.35% | ↓ 172.96% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 295.7M | ↑ 235.34% |
Net Income | -94.7M | ↓ 60.57% |
Net Profit Margin | -32.03% | ↑ 240.32% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 98.0M | ↓ 66.85% |
Net Income | -271.5M | ↑ 186.72% |
Net Profit Margin | -276.99% | ↓ 244.96% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 156.3M | ↑ 59.47% |
Net Income | -245.8M | ↓ 9.49% |
Net Profit Margin | -157.22% | ↑ 119.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 22.8M | ↑ 8.82% |
Net Income | -74.3M | ↑ 45.35% |
Net Profit Margin | -326.18% | ↓ 81.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 28.4M | ↑ 24.65% |
Net Income | -97.4M | ↑ 31.13% |
Net Profit Margin | -343.12% | ↓ 16.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.9M | ↓ 19.32% |
Net Income | -67.8M | ↓ 30.34% |
Net Profit Margin | -296.25% | ↑ 46.87% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.3M | ↑ 10.45% |
Net Income | -73.4M | ↑ 8.23% |
Net Profit Margin | -290.28% | ↑ 5.97% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.3M | ↓ 3.88% |
Net Income | -62.2M | ↓ 15.29% |
Net Profit Margin | -255.82% | ↑ 34.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 83.8M | ↑ 244.66% |
Net Income | -46.3M | ↓ 25.58% |
Net Profit Margin | -55.24% | ↑ 200.58% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 136.4M | ↓ 1.45% |
Total Liabilities | 310.9M | ↑ 45.15% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 155.3M | ↑ 13.88% |
Total Liabilities | 386.7M | ↑ 24.35% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 214.5M | ↑ 38.1% |
Total Liabilities | 426.0M | ↑ 10.17% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 466.0M | ↑ 117.22% |
Total Liabilities | 418.0M | ↓ 1.87% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 413.6M | ↓ 11.25% |
Total Liabilities | 468.5M | ↑ 12.06% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 313.9M | ↓ 24.09% |
Total Liabilities | 462.3M | ↓ 1.32% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 429.0M | ↓ 5.95% |
Total Liabilities | 440.9M | ↓ 0.38% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 413.6M | ↓ 3.6% |
Total Liabilities | 468.5M | ↑ 6.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 412.9M | ↓ 0.17% |
Total Liabilities | 466.0M | ↓ 0.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 383.6M | ↓ 7.09% |
Total Liabilities | 460.4M | ↓ 1.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 335.5M | ↓ 12.54% |
Total Liabilities | 450.8M | ↓ 2.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 313.9M | ↓ 6.43% |
Total Liabilities | 462.3M | ↑ 2.56% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -131.1M | ↑ 39.13% |
Investing Cash Flow | -3.6M | ↓ 273.98% |
Financing Cash Flow | 128.3M | ↑ 59.28% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.7M | ↓ 85.75% |
Investing Cash Flow | -4.7M | ↑ 29.69% |
Financing Cash Flow | 31.3M | ↓ 75.58% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -139.1M | ↑ 644.55% |
Investing Cash Flow | -4.4M | ↓ 4.64% |
Financing Cash Flow | 183.9M | ↑ 486.96% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.1M | ↓ 107.29% |
Investing Cash Flow | -43.2M | ↑ 871.63% |
Financing Cash Flow | 225.3M | ↑ 22.52% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -175.4M | ↓ 1828.66% |
Investing Cash Flow | -33.6M | ↓ 22.11% |
Financing Cash Flow | 95.8M | ↓ 57.46% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -32.2M | ↓ 25.92% |
Investing Cash Flow | -15.6M | ↑ 285.31% |
Financing Cash Flow | 28.2M | ↑ 1.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -47.3M | ↑ 47.05% |
Investing Cash Flow | -6.4M | ↓ 59.18% |
Financing Cash Flow | 23.8M | ↓ 15.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -58.5M | ↑ 23.63% |
Investing Cash Flow | -11.5M | ↑ 79.99% |
Financing Cash Flow | 56.3M | ↑ 136.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -44.5M | ↓ 23.99% |
Investing Cash Flow | 517.0K | ↓ 104.5% |
Financing Cash Flow | 38.3M | ↓ 31.98% |
Sell
Neutral
Buy
Agenus Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Agenus Inc | 18.09% | -25.91% | -57.99% | -79.48% | -76.9% |
Moderna, Inc. | 24.09% | 61.99% | -3.5% | -32.49% | 361.73% |
Regeneron Pharmaceuticals, Inc. | -1.4% | 14.78% | 16.74% | 91.89% | 178.31% |
Novo Nordisk A/s | -2.34% | 26.33% | 47.85% | 229.23% | 422.3% |
Vertex Pharmaceuticals Incorporated | -2.12% | 6.37% | 15.53% | 83.6% | 130.15% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Agenus Inc | 8.2 | NA | 0.0 | -6.1 | -12.79 | -0.28 | NA | -8.13 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Agenus Inc | Buy | $155.4M | -76.9% | 8.2 | -157.22% |
Moderna, Inc. | Buy | $41.7B | 361.73% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.31% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 422.3% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.15% | 28.81 | 36.68% |
BlackRock Inc
Deep Track Capital, LP
Vanguard Group Inc
Point72 Asset Management, L.P.
Sofinnova Ventures
Artal Group S A
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Organization | Agenus Inc |
Employees | 389 |
CEO | Dr. Garo H. Armen Ph.D. |
Industry | Health Technology |